Skip to main content
main-content
Erschienen in: Endocrine 1/2022

03.08.2022 | Original Article

Assessment of age as different variable types for determining survival in differentiated thyroid cancer

verfasst von: Li Genpeng, Shao Yuting, Wang Xinyi, Wei Tao, Gong Rixiang, Li Zhihui, Zhu Jingqiang, Lei Jianyong

Erschienen in: Endocrine | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The current tumor, node, metastasis (TNM) system uses an age of 55 years as a threshold for differentiated thyroid cancer (DTC). The aim of our study was to explore the concept of using age as a continuous variable.

Methods

A total of 36,559 patients with DTC in the Surveillance, Epidemiology, and End Results (SEER) database and 7491 patients in our centers were enrolled. Overall survival (OS) and cancer-specific survival (CSS) were compared. Furthermore, the different statistical model performance of the 6th edition TNM system and age cutoffs for papillary (PTC) and follicular thyroid cancer (FTC) were assessed. Then, a nomogram was built and validated to evaluate the efficacy of age as a continuous variable for predicting survival.

Results

The OS and CSS of patients with DTC were significantly increased in patients <55 years compared with those aged ≥55 years. However, no significant differences in prognosis were observed in certain groups as patients between 50 and 60 years were stratified by 1-year increments. Furthermore, the highest concordance index (C-index) was observed in the TNM staging without an age cutoff in SEER database (0.895), our two centers (0.877) and receiver operating characteristic (ROC) curves showed different age cutoffs for PTC and FTC. More importantly, the nomogram incorporating age as a continuous variable showed a favorable area under the ROC curve and calibration for training and validation groups.

Conclusions

The utilization of age as a continuous variable is a rational approach for predicting outcome in DTC patients.
Literatur
1.
Zurück zum Zitat A. Yt, A. Wc, A. Kk et al. Impacts of the American Joint Committee on Cancer (AJCC) 8(th) edition tumor, node, metastasis (TNM) staging system on outcomes of differentiated thyroid cancer in Thai patients. Heliyon 7(3), e06624 (2021) CrossRef A. Yt, A. Wc, A. Kk et al. Impacts of the American Joint Committee on Cancer (AJCC) 8(th) edition tumor, node, metastasis (TNM) staging system on outcomes of differentiated thyroid cancer in Thai patients. Heliyon 7(3), e06624 (2021) CrossRef
2.
Zurück zum Zitat I. Ganly, I.J. Nixon, L.Y. Wang et al. Survival from differentiated thyroid cancer: what has age got to do with it? Thyroid 25, 1106–1114 (2015) CrossRef I. Ganly, I.J. Nixon, L.Y. Wang et al. Survival from differentiated thyroid cancer: what has age got to do with it? Thyroid 25, 1106–1114 (2015) CrossRef
3.
Zurück zum Zitat P. Trimboli, A. Piccardo, A. Signore et al. Patient age is an independent risk factor of relapse of differentiated thyroid carcinoma and improves the performance of the American Thyroid Association Stratification System. Thyroid 30(5), 713–719 (2020) CrossRef P. Trimboli, A. Piccardo, A. Signore et al. Patient age is an independent risk factor of relapse of differentiated thyroid carcinoma and improves the performance of the American Thyroid Association Stratification System. Thyroid 30(5), 713–719 (2020) CrossRef
4.
Zurück zum Zitat K. Kim, K.K. Jin, C.R. Lee et al. Comparison of long-term prognosis for differentiated thyroid cancer according to the 7th and 8th editions of the AJCC/UICC TNM staging system. Ther. Adv. Endocrinol. Metab. 11, 2042018820921019 (2020) CrossRef K. Kim, K.K. Jin, C.R. Lee et al. Comparison of long-term prognosis for differentiated thyroid cancer according to the 7th and 8th editions of the AJCC/UICC TNM staging system. Ther. Adv. Endocrinol. Metab. 11, 2042018820921019 (2020) CrossRef
5.
Zurück zum Zitat E. Velsen, R.P. Peeters, M.T. Stegenga et al. Evaluating the use of a two-step age-based cutoff for the UICC/AJCC TNM staging system in patients with papillary or follicular thyroid cancer. Eur. J. Endocrinol. 186(3), 389–397 (2022) CrossRef E. Velsen, R.P. Peeters, M.T. Stegenga et al. Evaluating the use of a two-step age-based cutoff for the UICC/AJCC TNM staging system in patients with papillary or follicular thyroid cancer. Eur. J. Endocrinol. 186(3), 389–397 (2022) CrossRef
6.
Zurück zum Zitat M. Kim, Y.N. Kim, W.G. Kim et al. Optimal cut-off age in the TNM Staging system of differentiated thyroid cancer: is 55 years better than 45 years? Clin. Endocrinol. 86, 438–443 (2017) CrossRef M. Kim, Y.N. Kim, W.G. Kim et al. Optimal cut-off age in the TNM Staging system of differentiated thyroid cancer: is 55 years better than 45 years? Clin. Endocrinol. 86, 438–443 (2017) CrossRef
7.
Zurück zum Zitat I.J. Nixon, D. Kuk, V. Wreesmann et al. Defining a valid age cutoff in staging of well-differentiated thyroid cancer. Ann. Surg. Oncol. 23, 410–415 (2016) CrossRef I.J. Nixon, D. Kuk, V. Wreesmann et al. Defining a valid age cutoff in staging of well-differentiated thyroid cancer. Ann. Surg. Oncol. 23, 410–415 (2016) CrossRef
8.
Zurück zum Zitat J. Hendrickson-Rebizant, H. Sigvaldason, R.W. Nason et al. Identifying the most appropriate age threshold for TNM stage grouping of well-differentiated thyroid cancer. Eur. J. Surg. Oncol. 41, 1028–1032 (2015) CrossRef J. Hendrickson-Rebizant, H. Sigvaldason, R.W. Nason et al. Identifying the most appropriate age threshold for TNM stage grouping of well-differentiated thyroid cancer. Eur. J. Surg. Oncol. 41, 1028–1032 (2015) CrossRef
9.
Zurück zum Zitat E. Velsen, W.E. Visser, M.T. Stegenga et al. Finding the optimal age cutoff for the UICC/AJCC TNM staging system in patients with papillary or follicular thyroid cancer. Thyroid 31(7), 1041–1049 (2021) CrossRef E. Velsen, W.E. Visser, M.T. Stegenga et al. Finding the optimal age cutoff for the UICC/AJCC TNM staging system in patients with papillary or follicular thyroid cancer. Thyroid 31(7), 1041–1049 (2021) CrossRef
10.
Zurück zum Zitat M.A. Adam, S. Thomas, T. Hyslop et al. Exploring the relationship between patient age and cancer-specific survival in papillary thyroid cancer: rethinking current staging systems. J. Clin. Oncol. 34, 4415–4420 (2016) CrossRef M.A. Adam, S. Thomas, T. Hyslop et al. Exploring the relationship between patient age and cancer-specific survival in papillary thyroid cancer: rethinking current staging systems. J. Clin. Oncol. 34, 4415–4420 (2016) CrossRef
11.
Zurück zum Zitat Y. Dorina, K.D. Burman, V.N. Douglas et al. Eliminating the age cutoff in staging of differentiated thyroid cancer: the safest road? J. Clin. Endocrinol. Metab. 103, 1813–1817 (2018) CrossRef Y. Dorina, K.D. Burman, V.N. Douglas et al. Eliminating the age cutoff in staging of differentiated thyroid cancer: the safest road? J. Clin. Endocrinol. Metab. 103, 1813–1817 (2018) CrossRef
12.
Zurück zum Zitat S.L. Oyer, V.A. Smith, E.J. Lentsch, Reevaluating the prognostic significance of age in differentiated thyroid cancer. Otolaryngol. Head. Neck Surg. 147, 221–226 (2012) CrossRef S.L. Oyer, V.A. Smith, E.J. Lentsch, Reevaluating the prognostic significance of age in differentiated thyroid cancer. Otolaryngol. Head. Neck Surg. 147, 221–226 (2012) CrossRef
13.
Zurück zum Zitat R.K. Orosco, T. Hussain, K.T. Brumund et al. Analysis of age and disease status as predictors of thyroid cancer-specific mortality using the Surveillance, Epidemiology, and End Results database. Thyroid 25, 125–132 (2015) CrossRef R.K. Orosco, T. Hussain, K.T. Brumund et al. Analysis of age and disease status as predictors of thyroid cancer-specific mortality using the Surveillance, Epidemiology, and End Results database. Thyroid 25, 125–132 (2015) CrossRef
14.
Zurück zum Zitat R.L. Shi, N. Qu, T. Liao et al. The trend of age-group effect on prognosis in differentiated thyroid cancer. Sci. Rep. 6, 27086 (2016) CrossRef R.L. Shi, N. Qu, T. Liao et al. The trend of age-group effect on prognosis in differentiated thyroid cancer. Sci. Rep. 6, 27086 (2016) CrossRef
15.
Zurück zum Zitat L. Jianyong, Z. Jinjing, L. Zhihui et al. A nomogram based on the characteristics of metastatic lymph nodes to predict papillary thyroid carcinoma recurrence. Thyroid 28, 301–310 (2018) CrossRef L. Jianyong, Z. Jinjing, L. Zhihui et al. A nomogram based on the characteristics of metastatic lymph nodes to predict papillary thyroid carcinoma recurrence. Thyroid 28, 301–310 (2018) CrossRef
16.
Zurück zum Zitat R.L. Siegel, K.D. Miller, A. Jemal, Cancer statistics, 2020. CA Cancer J. Clin. 70(1), 7–30 (2020) CrossRef R.L. Siegel, K.D. Miller, A. Jemal, Cancer statistics, 2020. CA Cancer J. Clin. 70(1), 7–30 (2020) CrossRef
17.
Zurück zum Zitat A. Toumi, C. Digennaro, V. Vahdat et al. Trends in thyroid surgery and guideline-concordant care in the United States, 2007-2018. Thyroid 31(6), 941–949 (2021) CrossRef A. Toumi, C. Digennaro, V. Vahdat et al. Trends in thyroid surgery and guideline-concordant care in the United States, 2007-2018. Thyroid 31(6), 941–949 (2021) CrossRef
18.
Zurück zum Zitat D. Ahn, G.J. Lee, J.H. Sohn, Recurrence following hemithyroidectomy in patients with low- and intermediate-risk papillary thyroid carcinoma. Br. J. Surg. 107(6), 687–694 (2020) CrossRef D. Ahn, G.J. Lee, J.H. Sohn, Recurrence following hemithyroidectomy in patients with low- and intermediate-risk papillary thyroid carcinoma. Br. J. Surg. 107(6), 687–694 (2020) CrossRef
19.
Zurück zum Zitat L. Enewold, L.C. Harlan, J.L. Stevens, E. Sharon, Thyroid cancer presentation and treatment in the United States. Ann. Surg. Oncol. 22(6), 1789–1797 (2015) CrossRef L. Enewold, L.C. Harlan, J.L. Stevens, E. Sharon, Thyroid cancer presentation and treatment in the United States. Ann. Surg. Oncol. 22(6), 1789–1797 (2015) CrossRef
20.
Zurück zum Zitat M. Kim, Y.N. Kim, W.G. Kim et al. Optimal cut-off age in the TNM Staging system of differentiated thyroid cancer: is 55 years better than 45 years? Clin. Endocrinol. 86(3), 438–443 (2017) CrossRef M. Kim, Y.N. Kim, W.G. Kim et al. Optimal cut-off age in the TNM Staging system of differentiated thyroid cancer: is 55 years better than 45 years? Clin. Endocrinol. 86(3), 438–443 (2017) CrossRef
21.
Zurück zum Zitat Y. Ito, K. Ichihara, H. Masuoka et al. Establishment of an intraoperative staging system (iStage) by improving UICC TNM classification system for papillary thyroid carcinoma. World J. Surg. 34, 2570–2580 (2010) CrossRef Y. Ito, K. Ichihara, H. Masuoka et al. Establishment of an intraoperative staging system (iStage) by improving UICC TNM classification system for papillary thyroid carcinoma. World J. Surg. 34, 2570–2580 (2010) CrossRef
22.
Zurück zum Zitat A. Mazurat, A. Torroni, J. Hendrickson-Rebizant et al. The age factor in survival of a population cohort of well-differentiated thyroid cancer. Endocr. Connect 2, 154–160 (2013) CrossRef A. Mazurat, A. Torroni, J. Hendrickson-Rebizant et al. The age factor in survival of a population cohort of well-differentiated thyroid cancer. Endocr. Connect 2, 154–160 (2013) CrossRef
23.
Zurück zum Zitat M.C. Specht, M.W. Kattan, M. Gonen et al. Predicting nonsentinel node status after positive sentinel lymph biopsy for breast cancer: clinicians versus nomogram. Ann. Surg. Oncol. 12, 654–659 (2005) CrossRef M.C. Specht, M.W. Kattan, M. Gonen et al. Predicting nonsentinel node status after positive sentinel lymph biopsy for breast cancer: clinicians versus nomogram. Ann. Surg. Oncol. 12, 654–659 (2005) CrossRef
24.
Zurück zum Zitat P.L. Ross, C. Gerigk, M. Gonen et al. Comparisons of nomograms and urologists’ predictions in prostate cancer. Semin. Urol. Oncol. 20, 82–88 (2002) CrossRef P.L. Ross, C. Gerigk, M. Gonen et al. Comparisons of nomograms and urologists’ predictions in prostate cancer. Semin. Urol. Oncol. 20, 82–88 (2002) CrossRef
25.
Zurück zum Zitat J. Mohler, R.R. Bahnson, B. Boston, NCCN clinical practice guidelines in oncology: prostate cancer early detection. J. Natl Compr. Canc Netw. 8, 240–262 (2010) CrossRef J. Mohler, R.R. Bahnson, B. Boston, NCCN clinical practice guidelines in oncology: prostate cancer early detection. J. Natl Compr. Canc Netw. 8, 240–262 (2010) CrossRef
Metadaten
Titel
Assessment of age as different variable types for determining survival in differentiated thyroid cancer
verfasst von
Li Genpeng
Shao Yuting
Wang Xinyi
Wei Tao
Gong Rixiang
Li Zhihui
Zhu Jingqiang
Lei Jianyong
Publikationsdatum
03.08.2022
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 1/2022
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-022-03148-y

Weitere Artikel der Ausgabe 1/2022

Endocrine 1/2022 Zur Ausgabe

Neu im Fachgebiet Innere Medizin

Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Innere Medizin und bleiben Sie gut informiert – ganz bequem per eMail.